We identified three methylation biomarkers (IL1RAP, HIPK2 and CNMD) and validated their utility in differentiating FCD IIa from IIb in a larger replication study and an independent cohort of patients with epilepsy (Fig. 6). Here, HIPK2 is linked to epilepsy.